18:56 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Abingworth's BioVentures VII fund closes at $315M, exceeding target

Abingworth Management Ltd. closed its BioVentures VII fund at $315 million, exceeding the fund's $300 million target. Funds will be invested in the U.S. and Europe. Abingworth's therapeutic interests for BioVentures VII include next-generation cell...
18:49 , Jul 13, 2018 |  BioCentury  |  Finance

Curating Abingworth

With a narrower set of investment strategies and a diversified LP base for its latest fund, Abingworth is seeking double digit returns from the $315 million Bioventures VII. Abingworth’s Kurt von Emster told BioCentury the...
23:35 , Jul 9, 2018 |  BC Extra  |  Financial News

Abingworth closes BioVentures VII fund at $315M

Abingworth Management Ltd. closed its BioVentures VII fund at $315 million, exceeding the fund's $300 million target. Funds will be invested in the U.S. and Europe. Abingworth's therapeutic interests for BioVentures VII include next-generation cell...
15:37 , May 4, 2018 |  BC Week In Review  |  Financial News

Attenua raises $35M series A

Cough company Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round on April 30 in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and...
19:46 , Apr 30, 2018 |  BC Extra  |  Financial News

Cough company Attenua raises $35M series A, names CEO

Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and Redmile Group also participated. Attenua plans to start Phase II...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Company News

Catalyst Biosciences, Attenua deal

Catalyst will sell TC-5619, TC-6987 and TC-6683 (AZD1446) to Attenua for $1 million up front and for up to $105 million in milestones, plus royalties. Catalyst gained the products when it merged with Targacept Inc....